PFIZER INC. news, videos and press releases
For more news please use our advanced search feature.
PFIZER INC. - More news...
PFIZER INC. - More news...
- Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
- U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
- Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
- Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
- Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
- Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
- Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
- Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
- Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
- Pfizer Declares First-Quarter 2025 Dividend
- Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
- Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
- Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
- Pfizer Announces New Chief Scientific Officer and President, Research & Development
- European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
- U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
- Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma
- Pfizer Reports Second-Quarter 2023 Results
- Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy
- Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility
- Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
- FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
- FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
